JAK2 and myeloid neoplasm: Moreover, the 46/1 haplotype of JAK2, possibly a marker of inappropriate myeloid cell response to cytokine stimulation, has been shown to pre-dispose carriers to IBD and myeloid malignancies, notably MPNs (with or without mutation of JAK2) and acute myeloid leukemia (98, 99).